Key Drivers
- Strong gross-margin
- Heavy long-term debt
- Improving quarterly FCF
AIAI Summary
Bruker's shift from cyclical instrument sales to higher‑value spatial‑biology and proteomics commercialization materially increases upside, but the investment hinges on near‑term execution—specifically converting CellScape XR/portfolio launches into bookings, sustaining the recent Q4 FCF pickup over the next two quarters, and delivering the $100–$120M cost saves to meaningfully de‑risk heavy leverage. Monitor ACA/GOV order visibility, inventory turns, and any further intangible impairments as the primary signals that will validate or vaporize this upgraded upside case.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross-margin
- •Heavy long-term debt
- •Improving quarterly FCF
BRKR has durable gross margins and improving quarterly cash generation but faces thin annual profitability, heavy long-term debt and rich valuation that leave little margin for error.
Price Behavior
Key Price Behavior Insights:
- •Below last month average
- •Deep oversold RSI
- •Support held ~$32.8
BRKR is in a short-term downtrend below its last month average with RSI deep in the low‑20s (oversold), near-term support around $32.80 but resistance at $39–$41 could cap rallies until momentum recovers.
Persistent gap from
Sentiment & News
Key News Insights:
- •Product commercialization
- •Strategic collaborations
- •Divergent ownership
Bruker is accelerating commercialization of high‑throughput spatial biology with new CellScape XR and partnerships while institutional ownership shifts sharply—some funds adding large stakes as others trim positions.
Product launches and collaborations should drive revenue growth and commercial traction, while mixed institutional trading could increase near‑term share volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings